Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack

医学 氯吡格雷 替卡格雷 阿司匹林 冲程(发动机) 内科学 危险系数 随机对照试验 心脏病学 血小板聚集抑制剂 噻氯匹定 置信区间 机械工程 工程类
作者
Ronda Lun,Shan Dhaliwal,Gabriele Zitikyte,Danielle Carole Roy,Brian Hutton,Dar Dowlatshahi
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:79 (2): 141-141 被引量:30
标识
DOI:10.1001/jamaneurol.2021.4514
摘要

Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA). However, there is emerging evidence for the use of ticagrelor and aspirin, and the 2 DAPT regimens have not been compared directly.To compare ticagrelor and aspirin with clopidogrel and aspirin in patients with acute minor ischemic stroke or TIA in the prevention of recurrent strokes or death.MEDLINE, Embase, and Cochrane from database inception until February 2021.Randomized clinical trials that enrolled adults with acute minor ischemic stroke or TIA and provided the mentioned interventions within 72 hours of symptom onset, with a minimum follow-up of 30 days.PRISMA guidelines for network meta-analyses were followed. Two reviewers independently extracted data and appraised risk of bias. Fixed-effects models were fit using a bayesian approach to network meta-analysis. Between-group comparisons were estimated using hazard ratios (HRs) with 95% credible intervals (95% CrIs). Surface under the cumulative rank curve plots were produced.The primary outcome was a composite of recurrent stroke or death up to 90 days. Secondary outcomes include major bleeding, mortality, adverse events, and functional disability. A sensitivity analysis was performed at 30 days for the primary outcome.A total of 4014 citations were screened; 5 randomized clinical trials were included. Data from 22 098 patients were analyzed, including 5517 in the clopidogrel and aspirin arm, 5859 in the ticagrelor and aspirin arm, and 10 722 in the aspirin arm. Both clopidogrel and aspirin (HR, 0.74; 95% CrI, 0.65-0.84) and ticagrelor and aspirin (HR, 0.79; 95% CrI, 0.68-0.91) were superior to aspirin in the prevention of recurrent stroke and death. There was no statistically significant difference between clopidogrel and aspirin compared with ticagrelor and aspirin (HR, 0.94; 95% CrI, 0.78-1.13). Both DAPT regimens had higher rates of major hemorrhage than aspirin alone. Clopidogrel and aspirin was associated with a decreased risk of functional disability compared with aspirin alone (HR, 0.82; 95% CrI, 0.74-0.91) and ticagrelor and aspirin (HR, 0.85; 95% CrI, 0.75-0.97).DAPT combining aspirin with either ticagrelor or clopidogrel was superior to aspirin alone, but there was no statistically significant difference found between the 2 regimens for the primary outcome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Conran发布了新的文献求助10
1秒前
哈哈哈哈哈哈完成签到,获得积分20
2秒前
竹子发布了新的文献求助10
2秒前
刘浩然完成签到,获得积分10
3秒前
小蘑菇应助碧蓝醉蓝酱酱采纳,获得10
3秒前
An慧完成签到,获得积分10
6秒前
6秒前
ured发布了新的文献求助30
7秒前
9秒前
幽默不愁完成签到,获得积分10
10秒前
Tracy发布了新的文献求助10
11秒前
zs33完成签到,获得积分10
12秒前
Conran完成签到,获得积分10
13秒前
13秒前
Splaink完成签到 ,获得积分10
13秒前
ymlyang完成签到,获得积分10
13秒前
MaYue完成签到,获得积分10
13秒前
NexusExplorer应助朝暮行行采纳,获得10
14秒前
KYRIAL发布了新的文献求助10
14秒前
14秒前
叶瑾发布了新的文献求助10
14秒前
嘉平完成签到,获得积分10
15秒前
领导范儿应助Faiz采纳,获得10
16秒前
16秒前
16秒前
无花果应助bvuiragybv采纳,获得10
16秒前
16秒前
乐乐应助蓝色风筝采纳,获得10
17秒前
18秒前
研友_VZG7GZ应助Allonz采纳,获得10
18秒前
18秒前
Garfield完成签到 ,获得积分10
19秒前
orixero应助momo采纳,获得10
19秒前
叶瑾完成签到,获得积分10
20秒前
Katsura发布了新的文献求助10
21秒前
wy完成签到,获得积分10
21秒前
五五完成签到,获得积分20
21秒前
21秒前
23秒前
烟花应助天妒嘤才采纳,获得10
23秒前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
宽禁带半导体紫外光电探测器 300
Case Research: The Case Writing Process 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141967
求助须知:如何正确求助?哪些是违规求助? 2792975
关于积分的说明 7804827
捐赠科研通 2449305
什么是DOI,文献DOI怎么找? 1303150
科研通“疑难数据库(出版商)”最低求助积分说明 626807
版权声明 601291